Mesenchymal stem/stromal cells (MSC) have been transplanted for therapeutic purposes with inconsistent results. MSC preparations are heterogeneous, and this person-to-person heterogeneity may account for the variable clinical outcomes. Additionally, the mechanisms of therapeutic action for MSC are unclear which confounds attempts to understand and identify factors that may account for variable clinical results. Here, we report our analysis of MSC preparations for the expression levels of molecules that have been hypothesized to mediate MSC function. Although most of the analytes assessed demonstrated little divergent expression, several molecules were found with enhanced heterogeneity both within individual MSC preparations and among MSC preparations from the sample of multiple sclerosis patients. The variable expression of these molecules may relate to the therapeutic heterogeneity of MSC. Additionally, we found a novel set of molecules that were highly intercorrelated in MSC. The tight association of this group of molecules may represent an invariant molecular organization that is integral to MSC activity. The precise analysis of molecular expression levels in MSC has the potential to answer concerns about variable therapeutic effects of MSC transplantation as well as to understand the mechanism of clinical effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.beha.2025.101596 | DOI Listing |
Best Pract Res Clin Haematol
December 2024
Mellen Center, Neurological Institute, Cleveland Clinic Foundation, United States.
Mesenchymal stem/stromal cells (MSC) have been transplanted for therapeutic purposes with inconsistent results. MSC preparations are heterogeneous, and this person-to-person heterogeneity may account for the variable clinical outcomes. Additionally, the mechanisms of therapeutic action for MSC are unclear which confounds attempts to understand and identify factors that may account for variable clinical results.
View Article and Find Full Text PDFJ Addict Nurs
March 2025
Kristine Nicki Annunziata, RGN, MA, Elizabeth A. Curtis, PhD, MA, MEd, and Catherine M. Comiskey, BA (Mod), MA, MSc, PhD, FTCD, School of Nursing and Midwifery, Trinity College Dublin, The University of Dublin, Ireland.
Background: Vicarious trauma (VT) can have major negative consequences for those working with patients who have experienced trauma. The topic has been investigated for over three decades, and yet, the role of VT among nurses working in addiction services remains underresearched.
Aim: The aims of this study were to identify what is known and to report on the gaps in the literature on VT among nurses working in addiction services.
Semin Arthritis Rheum
February 2025
James B. Wyngaarden Professor Emeritus of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address:
Preclinical models of inherited and induced autoimmune diseases (AIDs) have shown that hematopoietic stem cell transplantation (HSCT) following high-dose immunosuppressive conditioning could reverse organ damage and alter the course of AIDs. The rationale for both autologous and allogeneic HSCT has been based upon a reset of the immune system. Clinical application of HSCT was initially focused on severe systemic sclerosis (SSc) and three randomized trials comparing autologous HSCT with standard cyclophosphamide (CY) demonstrated significant improvement in SSc measured 12-54 months after transplant.
View Article and Find Full Text PDFMethods
March 2025
Université Sorbonne Paris Nord, INSERM U1148, Laboratory for Vascular Translational Science, Cardiovascular Bioengineering, 99 Av. Jean-Baptiste Clément 93430 Villetaneuse, France. Electronic address:
The potential of the cell lysate, secretome and extracellular vesicles (EVs) of mesenchymal stem cells (MSCs) to modulate the immune response and promote tissue regeneration has positioned them as a promising option for cell-free therapy. Currently many clinical trials in stem cells-derived EVs and secretome are in progress for an extensive variety of diseases and sometimes the results are failing. The major challenge on this roadmap is the lack of a standard extraction method for exosome, secretome and lysate.
View Article and Find Full Text PDFHealth Secur
March 2025
Kazuaki Jindai, MD, DrPH, is an Epidemiologist and Infectious Diseases Specialist, Department of Virology, Tohoku University Graduate School of Medicine, Sendai; and an Internal Medicine Physician, Meiseikai Healthcare Corporation, and AMR team lead, Allm Inc., Tokyo, Japan. Hiroki Saito, MD, MPH, PhD, is an Infectious Diseases/Critical Care Specialist and Researcher, Interdepartmental Division of Critical Care Medicine, Department of Medicine, University of Toronto, Toronto, Canada, and is associated with Department of Emergency and Critical Care Medicine, St Marianna University School of Medicine, Kawasaki, Japan. Eriko Morino, MD, is a Clinical Trial Specialist, Center for Clinical Sciences, National Center for Global Health and Medicine, and is associated with the Department of Respiratory Medicine, National Center for Global Health and Medicine, and the Department of Infectious Diseases, Keio University School of Medicine; all in Tokyo, Japan. Ryota Hase, MD, is an Infectious Disease Specialist and Chief, Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Narita, Japan. Masaya Yamato, MD, PhD, is an Infectious Disease/Critical Care Specialist and Chief, Center for Infectious Diseases, Rinku General Medical Center, Izumisano, Japan. Miwa Sonoda, RN, MPH, is a Clinical Trial Specialist, Department of International Trials, National Center for Global Health and Medicine, Tokyo, Japan. Taro Shibata, MSc, is a Biostatistician and Chief, Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan. Tatsuo Iiyama, MD, is a Clinical Trial Specialist, Department of International Trials, National Center for Global Health and Medicine, Tokyo, Japan.
In Japan, the Infectious Disease Control Law designates certain institutions across the country as medical institutions for infectious diseases, with the role to respond to and prepare for epidemic or pandemic infections. Since the early stages of the COVID-19 pandemic, these designated medical institutions have provided clinical care to patients with COVID-19. While these institutions primarily handle clinical care, they are also well poised to conduct rigorous clinical research that is needed to address future health emergencies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!